News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
Fosun Pharma (02196.HK) FKC289 Injection Clinical Trial Approved
Fosun Pharma (02196.HK) announced that its subsidiary Fosun Kairui has received approval from the National Medical Products Administration to conduct Phase I/II clinical trials of ...
Reset
Send
The window will close in 5 seconds
Fosun Pharma (02196.HK) FKC289 Injection Clinical Trial Approved
Close
Recommend
2
Positive
3
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

Fosun Pharma (02196.HK)  -0.080 (-0.458%)    Short selling $1.45M; Ratio 4.045%   announced that its subsidiary Fosun Kairui has received approval from the National Medical Products Administration to conduct Phase I/II clinical trials of FKC289 injection for relapsed/refractory primary light-chain amyloidosis and relapsed/refractory membranous nephropathy. Fosun Kairui plans to carry out the relevant clinical studies of the drug in mainland China once conditions are met.

As of March 2026, the Group's cumulative R&D investment in FKC289 at the current stage amounted to approximately RMB59 million. (ss/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-22 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.